Sulpiride (cas 15676-16-1) microemulsions as antipsychotic nasal drug delivery systems: In-vitro and pharmacodynamic study
-
Add time:09/03/2019 Source:sciencedirect.com
The present study aimed to develop microemulsion (ME) formulae for nasal delivery of Sulpiride (cas 15676-16-1) with high drug concentration to overcome sulpiride low oral bioavailability. Different oils, surfactants (S) and co-surfactants (CoS) were screened for the highest sulpiride solubilizing capacity. Glycerylmonooleate (GMO), Labrafil and Avocado were chosen as oily phases for ternary phase diagram construction. As nasal cavity accommodates limited administration volume, higher drug solubility and ME area (AT %) were used as assessment criteria. ME systems of the highest drug solubilities were subjected to physicochemical characterization such as drug content, pH, refractive index (RI), percent transmittance (%T), in-vitro release and ex-vivo permeation through the sheep nasal mucosa. Sulpiride solubility increased to 43.35 mg/ml with drug content more than 97%. The pH ranged from 4.25 to 5.75 while RI and %T values indicated that o/w type ME was formed. The pharmacodynamic performance, antipsychotic activity of sulpiride, concluded that intranasal ME is an effective alternate therapy for schizophrenia.
We also recommend Trading Suppliers and Manufacturers of Sulpiride (cas 15676-16-1). Pls Click Website Link as below: cas 15676-16-1 suppliers
Prev:Original ResearchAssociation of Deslorelin and Sulpiride (cas 15676-16-1) for Double Ovulation Induction in Mares
Next:Original ResearchEffects of Combined Estradiol-Sulpiride (cas 15676-16-1) Treatment and Follicle Ablation on Vernal Transition in Mares: Evaluation of Plasma and Follicular Fluid Hormones and Luteinizing Hormone Receptor Gene Expression) - 【Back】【Close 】【Print】【Add to favorite 】
- Related Information
- Research ArticlePharmacokinetics, Pharmacodynamics and Drug Transport and MetabolismPossible Role of Organic Cation Transporters in the Distribution of [11C]Sulpiride (cas 15676-16-1), a Dopamine D2 Receptor Antagonist09/08/2019
- Original ResearchFactors Affecting the Ovarian Response to a Combined Estradiol-Sulpiride (cas 15676-16-1) Treatment in Seasonally Anovulatory Mares09/07/2019
- Original ResearchThe Effect of Sulpiride (cas 15676-16-1) Treatment During the Periovulatory Period on Prolactin Concentration and Ovulation in the Mare09/06/2019
- Original ResearchLong-term and Short-term Dopaminergic (Cabergoline) and Antidopaminergic (Sulpiride (cas 15676-16-1)) Effects on Insulin Response to Glucose, Glucose Response to Insulin, or Both in Horses09/05/2019
- Original ResearchEffects of Combined Estradiol-Sulpiride (cas 15676-16-1) Treatment and Follicle Ablation on Vernal Transition in Mares: Evaluation of Plasma and Follicular Fluid Hormones and Luteinizing Hormone Receptor Gene Expression09/04/2019
- Original ResearchAssociation of Deslorelin and Sulpiride (cas 15676-16-1) for Double Ovulation Induction in Mares09/02/2019
- Original ResearchEffects of Various Methods of Sulpiride (cas 15676-16-1) Administration on Prolactin Release in Horses09/01/2019